Spots Global Cancer Trial Database for soft tissue sarcoma
Every month we try and update this database with for soft tissue sarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | NCT03114527 | Soft Tissue Sar... | Ribociclib Everolimus | 18 Years - | Fox Chase Cancer Center | |
| Prehabilitation Soft-Tissue Sarcoma of Lower Limb | NCT04518488 | Soft Tissue Sar... | Exercises Informational S... | - | McGill University | |
| A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma | NCT00001300 | Sarcoma | doxorubicin ifosfamide mesna | - | National Institutes of Health Clinical Center (CC) | |
| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | NCT05229601 | Soft Tissue Sar... Renal Cell Carc... Uterine Carcino... Hepatocellular ... Head and Neck S... Melanoma | HFB301001 | 18 Years - | HiFiBiO Therapeutics | |
| The Effects of Observer Presence and Type on Patients' Perception of Exercise in Patients With Soft Tissue Sarcoma | NCT05596565 | Soft Tissue Sar... | Supervised Exer... | 18 Years - 65 Years | Istanbul Medeniyet University | |
| E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma | NCT00413192 | Soft Tissue Sar... | E7389 | 18 Years - | Eisai Inc. | |
| Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma | NCT01382030 | Soft Tissue Sar... | EIA chemotherap... | 18 Years - 65 Years | Heidelberg University | |
| Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment | NCT05926700 | Soft Tissue Sar... | Candonilimab | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | NCT00288444 | Lung Cancer Soft Tissue Sar... Colorectal Carc... Breast Cancer Prostate Cancer | Lonafarnib Docetaxel | - | Emory University | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | NCT02867592 | Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor | Cabozantinib Cabozantinib S-... Pharmacological... | 2 Years - 30 Years | National Cancer Institute (NCI) | |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | NCT04969835 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... Head and Neck C... Cancer of Unkno... Ovarian Cancer Breast Cancer Soft Tissue Sar... Bladder Cancer Oesophageal Can... Prostate Cancer Biliary Tract C... | AVA6000 | 18 Years - | Avacta Life Sciences Ltd | |
| Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT) | NCT05761054 | Soft Tissue Sar... | RT | 18 Years - | Azienda Ospedaliero-Universitaria Careggi | |
| 5-Day Preoperative Radiation for Soft Tissue Sarcoma | NCT06087861 | Soft Tissue Sar... | External Beam R... | 18 Years - | Stanford University | |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | NCT04969835 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... Head and Neck C... Cancer of Unkno... Ovarian Cancer Breast Cancer Soft Tissue Sar... Bladder Cancer Oesophageal Can... Prostate Cancer Biliary Tract C... | AVA6000 | 18 Years - | Avacta Life Sciences Ltd | |
| Huntsman Biopsy Study | NCT00615329 | Soft Tissue Sar... Osteosarcoma | - | State University of New York - Upstate Medical University | ||
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | NCT02451943 | Soft Tissue Sar... | Olaratumab Doxorubicin Placebo | 18 Years - | Eli Lilly and Company | |
| Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma | NCT05656144 | Soft Tissue Sar... | Cadonilimab | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | NCT05655598 | Advanced Breast... Treatment-Refra... Retinoblastoma ... SCLC Soft Tissue Sar... Endometrial Can... Bladder Cancer | Palbociclib Ora... TAS-116 TAS-116 TAS-116 | 18 Years - | Brown University | |
| Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma | NCT03890068 | Soft Tissue Sar... | Anlotinib Hydro... | 18 Years - 70 Years | Sun Yat-sen University | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma | NCT04776525 | Soft Tissue Sar... | Ifosfamide Doxorubicin | 18 Years - | Oslo University Hospital | |
| Study of Low Dose CT in Sarcoma Patients | NCT00188422 | Soft Tissue Sar... | low dose CT | 16 Years - | University Health Network, Toronto | |
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma | NCT01684449 | Advanced Soft T... | Gemcitabine + R... | 18 Years - 70 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment | NCT02812654 | Sarcoma, Soft T... | Doxorubicin Ifosfamide radiotherapy | 18 Years - 75 Years | AC Camargo Cancer Center | |
| Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma | NCT01498835 | Soft Tissue Sar... | Sunitinib | 18 Years - | Heidelberg University | |
| Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | NCT00179816 | Ewing's Sarcoma Soft Tissue Sar... Hepatoblastoma Hodgkin's Disea... Germ Cell Tumor | High-Dose Chemo... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma | NCT00626704 | Locally Advance... Sarcoma Soft Tissue Sar... | AMG 655 Placebo Doxorubicin | 18 Years - | Amgen | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | NCT03168061 | Solid Tumor Soft Tissue Sar... Metastatic Sarc... Sarcoma | NC 6300 | 18 Years - 80 Years | NanoCarrier Co., Ltd. | |
| Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma | NCT03116529 | Soft Tissue Sar... | Combination Rad... | 18 Years - | University of Maryland, Baltimore | |
| Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS) | NCT00918489 | Soft Tissue Sar... | Vorinostat | 18 Years - | Heidelberg University | |
| Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy | NCT05944913 | Soft Tissue Sar... | Prevena | 18 Years - | Centre Leon Berard | |
| Huntsman Biopsy Study | NCT00615329 | Soft Tissue Sar... Osteosarcoma | - | State University of New York - Upstate Medical University | ||
| Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | NCT04106492 | Cancer | SQ3370 | 18 Years - | Shasqi, Inc. | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy | NCT02300545 | Sarcoma, Soft T... Soft Tissue Sar... | Pazopanib | 18 Years - | Washington University School of Medicine | |
| A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma | NCT05755113 | Soft Tissue Sar... | Tigilanol Tigla... | 18 Years - | QBiotics Group Limited | |
| Radiation Therapy to Treat Musculoskeletal Tumors | NCT00186992 | Sarcoma, Ewing'... Rhabdomyosarcom... Soft Tissue Sar... Musculoskeletal... | image-guided ra... | - 25 Years | St. Jude Children's Research Hospital | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall | NCT02634710 | Soft Tissue Sar... | Hypofractionate... | 18 Years - | Medical College of Wisconsin | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma | NCT00541840 | Soft Tissue Sar... | Sorafenib | 18 Years - 72 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure | NCT01136499 | Soft Tissue Sar... | LBH589 (Panobin... | 18 Years - | Centre Leon Berard | |
| Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology | NCT01696760 | Bone Metastases Musculoskeletal... Soft Tissue Sar... Thromboembolism | acetylsalicylic... enoxaparin PCD | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | NCT03449108 | Bone Sarcoma Dedifferentiate... Giant Cell Tumo... Malignancy in G... Malignant Solid... Ovarian Carcino... Platinum-Resist... Poorly Differen... Recurrent Osteo... Recurrent Ovari... Refractory Oste... Soft Tissue Sar... Thyroid Gland A... Thyroid Gland S... Undifferentiate... Triple Negative... | Aldesleukin Autologous Tumo... Autologous Tumo... Cyclophosphamid... Fludarabine Ipilimumab Nivolumab Quality-of-Life... Questionnaire A... | 16 Years - 70 Years | M.D. Anderson Cancer Center | |
| Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma | NCT04910126 | Soft Tissue Sar... Neoplasms, Conn... Sarcoma Metasta... Sarcoma,Soft Ti... | Camrelizumab Adriamycin | 18 Years - 60 Years | Wuhan Union Hospital, China | |
| Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. | NCT05189483 | Soft Tissue Sar... | Albumin-Bound P... Camrelizumab | 16 Years - 70 Years | Henan Cancer Hospital | |
| Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients | NCT05051059 | Soft Tissue Sar... Bone Sarcoma | Functional outc... Health related ... | 18 Years - 95 Years | Universitaire Ziekenhuizen KU Leuven | |
| NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | NCT03524898 | Soft Tissue Sar... | Nab-Paclitaxel gemcitabine | 18 Years - | Swiss Group for Clinical Cancer Research | |
| OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients | NCT03698227 | Advanced Soft T... | Olaratumab Dexrazoxane Doxorubicin | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) | NCT02449343 | Soft Tissue Sar... | Anlotinib Placebo | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Pre-operative Hypofractionated Proton Therapy | NCT05917301 | Soft Tissue Sar... | hypofractionati... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine | NCT05697198 | Lung Cancer Ovarian Cancer Uterine Cancer Colorectal Canc... Stomach Cancer Esophageal Canc... Pancreatic Canc... Melanoma Breast Cancer Head and Neck C... Soft Tissue Sar... Rhabdomyosarcom... Prostate Cancer | OmniSeq Test | 18 Years - | Labcorp Corporation of America Holdings, Inc | |
| Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma | NCT01382030 | Soft Tissue Sar... | EIA chemotherap... | 18 Years - 65 Years | Heidelberg University | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma | NCT01055028 | Angiosarcomas Soft Tissue Sar... | Bevacizumab Paclitaxel | 18 Years - | Stanford University | |
| Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma | NCT01719744 | Advanced Metastatic Soft Tissue Sar... | ENMD-2076 | 18 Years - | University Health Network, Toronto | |
| Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | NCT01005797 | Renal Cancer Non Small Cell ... Soft Tissue Sar... | Panobinostat (L... | 18 Years - | Medical University of South Carolina | |
| Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study | NCT03546127 | Colorectal Carc... Soft Tissue Sar... | Next Generation... | 18 Years - | Institut National de la Santé Et de la Recherche Médicale, France | |
| A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | NCT06171282 | Osteosarcoma Sarcoma Soft Tissue Sar... Bone Tumor | Recombinant onc... | 16 Years - 75 Years | Shanghai Yunying Medical Technology | |
| Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease | NCT02080897 | Soft Tissue Sar... Metastatic Lung... | 18 Years - | Duke University | ||
| Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study | NCT00611078 | Soft Tissue Sar... | 18 Years - 79 Years | Memorial Sloan Kettering Cancer Center | ||
| Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy | NCT00753688 | Sarcoma, Soft T... | PAZOPANIB Placebo | 18 Years - | GlaxoSmithKline | |
| Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide | NCT00629343 | Soft Tissue Sar... Mesothelioma | Azacitidine In ... | 18 Years - | Columbia University | |
| Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | NCT05043649 | Advanced Soft-t... | Camsirubicin | 18 Years - | Monopar Therapeutics | |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers | NCT05582031 | Anal Squamous C... Colorectal Neop... Soft Tissue Sar... Malignant Pleur... Small Cell Lung... Castrate Resist... Neuroendocrine ... Gastroenteropan... | Regorafenib in ... | 18 Years - | Translational Research in Oncology | |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | NCT02549937 | Tumors | surufatinib | 18 Years - | Hutchmed | |
| Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | NCT04040205 | Chondrosarcoma Osteosarcoma Soft Tissue Sar... | Abemaciclib | 18 Years - | Medical College of Wisconsin | |
| Sarcomas and DDR-Inhibition; a Combined Modality Study | NCT05116254 | Soft Tissue Sar... | AZD1390 + radio... AZD1390 + durvl... | 18 Years - | The Netherlands Cancer Institute | |
| Adriamycin and Ifosfamide Combined With Sintilimab | NCT04589754 | Soft Tissue Sar... | Sintilimab plus... Adriamycin-base... | 14 Years - 70 Years | Sun Yat-sen University | |
| Dalteparin in Preventing DVT in Participants With Cancer | NCT00525057 | Bone Sarcoma Femur Fracture Lymphoma Metastatic Neop... Pathologic Frac... Plasma Cell Mye... Soft Tissue Sar... | Dalteparin | 30 Years - | M.D. Anderson Cancer Center | |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | NCT02451943 | Soft Tissue Sar... | Olaratumab Doxorubicin Placebo | 18 Years - | Eli Lilly and Company | |
| Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma | NCT05656144 | Soft Tissue Sar... | Cadonilimab | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | NCT03104335 | Soft Tissue Sar... Advanced Cancer | Apatinib | 16 Years - | Peking University People's Hospital | |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | NCT04145349 | Desmoplastic Sm... | Ramucirumab Cyclophosphamid... Vinorelbine | 12 Months - 29 Years | Eli Lilly and Company | |
| 5-Day Preoperative Radiation for Soft Tissue Sarcoma | NCT06087861 | Soft Tissue Sar... | External Beam R... | 18 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
